Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Literature
1.
Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, Altman JK, Douer D, Rowe JM, Tallman MS (2011) Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 118(5):1248–1254CrossRefPubMedPubMedCentral
2.
Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgård L, Derolf AR, Stockelberg D, Tidefelt U, Wahlin A, Wennström L, Höglund M, Juliusson G (2011) Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia 25(7):1128–1134CrossRefPubMed
3.
Mantha S, Goldman DA, Devlin SM, Lee JW, Zannino D, Collins M, Douer D, Iland HJ, Litzow MR, Stein EM, Appelbaum FR, Larson RA, Stone R, Powell BL, Geyer S, Laumann K, Rowe JM, Erba H, Coutre S, Othus M, Park JH, Wiernik PH, Tallman MS (2017) Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood 129(13):1763–1767CrossRefPubMedPubMedCentral
4.
de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, Esteve J, Bergua JM, Milone G, Debén G, Rivas C, González M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 111(7):3395–3402CrossRefPubMed
5.
Malhotra P, Varma N, Arora N, Das R, Nath A, Patel FD, Varma S (2010) Treatment of therapy related acute promyelocytic leukemia with the combination of all trans retinoic acid and arsenic trioxide without chemotherapy: a series of three patients. Leuk Lymphoma 51(5):933–936CrossRefPubMed
6.
Elsayed A, Elgamal E, Elsayed AA, Wasserberg J, Kuncz A (2016) Non-surgical treatment of massive traumatic corpus callosum hematoma after blunt head injury: a case report. Neurol Neurochir Pol. 50(4):309–312CrossRefPubMed
Metadata
Title
Corpus Callosum Bleed: A Rare Presentation of Acute Promyelocytic Leukemia
Authors
Aditya Jandial
Kundan Mishra
Mithun Sekhar
Rajeev Sandal
Deepesh Lad
Gaurav Prakash
Alka Khadwal
Jasmina Ahluwalia
Pankaj Malhotra
Publication date
01-04-2019
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2019
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-018-1042-x

Other articles of this Issue 2/2019

Indian Journal of Hematology and Blood Transfusion 2/2019 Go to the issue

Original Article

Outcome of Acute Myeloid Leukemia in Children Adolescents and Young Adults Treated with an Uniform Protocol in Casablanca, Morocco

Original Article

After Hour Blood Transfusions: A Transfusion Service Perspective

Original Article

Impact of Genotype of Beta Globin Gene on Hepatic and Myocardial Iron Content in Egyptian Patients with Beta Thalassemia

Review Article

CRISP Points on Establishing CRISPR-Cas9 In Vitro Culture Experiments in a Resource Constraint Haematology Oncology Research Lab

Original Article

Efficacy of Thromboelastography (TEG) in Predicting Acute Trauma-Induced Coagulopathy (ATIC) in Isolated Severe Traumatic Brain Injury (iSTBI)

Original Article

Mutational Analysis of Bombay Phenotype in Iranian People: Identification of a Novel FUT1 Allele
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits